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1. Introduction 
In 1967 Cotzias et al. [l] suggested that the 
melanocyte-stimulating hormone (MSH) of the pituit- 
ary may aggravate the tremor in Parkinson’s disease 
and more recently Shuster et al. [2] found increased 
&MSH levels in parkinsonian patients. The secretion 
of MSH from the pituitary is influenced by the hypo- 
thalamus [3] and the structure of a hypothalamic 
melanocyte-stimulating hormone release-inhibiting 
factor (MIF) has been proposed to be that of a tripep- 
tide, prolylleucylglycinamide (Pro-Leu-Gly-NHz) 
[4,51. 
Oxotremorine has often been employed to produce 
in experimental animals a very simple and reproduci- 
ble model of Parkinson’s disease. It has been shown by 
Everett et al. [6] that L-dopa, used clinically in the 
treatment of Parkinsonism, will inhibit the tremor 
induced by oxotremorine. Studies in mice by Plotnikoff 
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et al. [7] have demonstrated that also MIF reduces 
the tremor caused by oxotremorine and that MIF 
appears to potentiate the behavioral effects of 
L-dopa [8]. 
When evaluated together all these findings seem to 
indicate that natural MIF may have some influence 
upon the general syndrome of Parkinson’s disease. 
In a preliminary clinical study Kastin and Barbeau 
[9] found that MIF posesses ome antiparkinsonian 
activity, but they concluded that the number of 
patients studied was not large enough for claiming any 
therapeutic applications. 
The tremor reducing ability of MIF appears to be 
independent of its MSH-release inhibiting activity, 
since the tremor was reduced in normal as well as in 
hypophysectomized mice [7]. In order to investigate 
whether peptides related to MIF or other hypothalam- 
ic neurohormones [3] could antagonize the effects of 
oxotremorine we have synthesized and tested six 
tripeptides for inhibition of oxotremorine-induced 
tremor in mice. These peptides are MIF, the thyro- 
tropin releasing hormone (TRH) of the hypothalamus 
[ IO,1 l] , LGlu-Thi-Pro-NHz (1) (Thi = p-(2- 
thienyl)-L-alanine), plu-Leu-Gly-NH2 (2) 
mlu-Leu-Pro-NH2 (3) and Qlu-Gly-Pro-NH2 
(4). (The nomenclature of the amino acids and peptid- 
es follow the IUPAC-IUB recommendations 1972). 
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2. Materials and methods 
The synthesis of the peptides has been effected by 
classical methods in solution. TRH, which ismlu- 
His-Pro-NH2 , was prepared as described by Chang 
et al. [ 121 .mlu-Thi-Pro-NH* (1),mlu-Leu- 
Pro-NH* (3) andalu-Gly-Pro-NH? (4) were 
synthesized as reported by Sievertsson et al. [ 131. For 
these four peptides the reported physical data [ 12, 
131 were again observed. 
In the synthesis of MIF andmlu-Leu-Gly-NH2 
(2) the following steps were utilized. Z-Leu-ONp 
was coupled with Gly-NH2 in dimethylformamide 
(DMF) and the resulting protected dipeptide Z-Leu- 
Gly-NH2 was then treated with HBr in HOAc yield- 
ing Leu-Gly-NH? . HBr. After neutralization with 
triethylamine the latter dipeptide was coupled with 
Z-Pro-ONp in DMF, giving Z-Pro-Leu-Gly-NHz, 
which after catalytic hydrogenation at room tempera- 
ture and atmospheric pressure yielded Pro-Leu-Gly- 
NH2 (MIF). Leu-Gly-NH* was also coupled with 
mlu-OPcp [ 141 to give Qlu-Leu-Gly-NH* (2). 
Chemical and physical data of these latter peptides 
are collected in table 1. 
Antagonism of oxotremorine induced tremor was 
estimated using the electronic device described by 
Silverman and Jenden [ 151. The use of this objective 
method ensures reliable measurements of the tremor 
intensities [ 161 .
Mice were individually placed in a light bowl 
resting in the cone of a Quam 16 A6PA moving coil 
loudspeaker, and an amplifier with a sharp bandpass 
from 20.0-24.6 Hz was used to amplify selectively 
the signals generated by the tremor. Signals generated 
by random movement were rejected. The amplified 
signal was rectified and integrated over periods of 
1 min with an integrator, of essentially infinite time 
constant, which was reset automatically at 1 min time 
intervals. The integrator output was recorded on a 
potentiometric recorder. The total response during a 
3 min period following intravenous injection of oxo- 
tremorine was used as a measure of the drug response. 
The ‘up and down’ method for small samples des- 
cribed by Dixon [ 171 was used to estimate the median 
effective dose of oxotremorine. The response was 
recorded as positive or negative depending on whether 
it was greater or less than a predetermined threshold 
which corresponded approximately to the mean 
response to 120 pg/kg of oxotremorine. 
Oxotremorine was administered to groups of 5 
male mice (Swiss-Webstor) weighing 20-29 g and the 
median effective dose was determined. A logarithmic 
series of doses of oxotremorine with a spacing of 0.1 
units in the Loglo dose scale was used. The tested 
peptides were administered intraperitoneally 1 hr be- 
fore the oxotremorine, and tremors were measured 
for a 3 min period, starting 20 set after the intravenous 
administration of oxotremorine, Four to five doses 
including zero were chosen for each peptide. 
The median effective dose of oxotremorine was 
plotted against the dose of the tested peptide (fig. 1). 
The peptides that showed no significant linear regres- 
Table 1 
Chemical and physical data of MIF,Qlu’ -MIF, and intermediary peptides 
Yield R; 
% 
R; R;* m.p. (“C)/[oll g 
Z-Leu-Giy-NH, 
Leu-Gly-NH,.HBr 
Z-Pro-Leu-Gly-NH, 
Pro-Leu-Gly-NH,(MIF) 
mlu-Leu-Gly-NH, (2) 
96 - 
100 0.75 
37 0.95 
89 0.72 
31 0.83 
0.73 0.82 78”/-9.8 (c 2.5, CHCL,)** 
0.58 0.19 - 
0.92 0.85 162-163”/-71.1 (c 1.4,EtOH)*** 
0.18 0.68 112-113, So/-48.8 (c l.O,MeOH)t 
0.85 0.57 175- 176”/-17.0 (c l.O,MeOH)tt 
* R;, R; and R: refer to tic on silica gel (Merck F 254 precoated plates) in HOAc:EtO_Ac:BuOH:H,O (1: 1: 1: l), 
EtOH:H,O:EtOAc (i:4:8) and CHCl,:MeOH:NH, (50:20:5) respectively (R; 0.62, Rt 0.73, Ri 0.23 for Phe). 
** Lit. 80”/-10.5 (c 1.8, CHCl,) [21]. 
*** Lit. 163’/-71.9 (c 2.5, EtOH) [21] ; 163” [22,23]. 
t Lit. 120” [21]; 122-123” [23]. 
tt Lit. 174-175”/-17.7 (c 0.9, MeOH) [24]. 
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io i0 30 d0 
Dose of “antagonist” (mglkg) 
Fig. 1. Median effective dose of oxotremorine (OT) estimated by the ‘up and down’ method for small samples, plotted against he 
dose of ‘antagonist’. The figures within parentheses refer to the peptides described in the text. 
Table 2 
Pharmacological results in mice 
Compound In vivo dose (i.p.) to pro- 
duce oxotremorine 
blockade 
Pro-Leu-Gly-NH, 
mlu-His-Pro-NH, 
LCrh-Thi-Pr0-NH, 
mlu-Leu-Gly-NH, 
mlu-Leu-Pro-NH, 
LQu-Gly-Pro-NH, 
-CH, -C=CCH, 
MIF 
TRH 
(1) 
(2) 
(3) 
(‘0 
mg/kg Ctmol/kg 
30 (22-42) 105** 
inactive 
8.0 (3.0-19) 21* 
19 (13-31) 65** 
inactive 
inactive 
(3 2.9 (0.3-8.8) 12* 
* 90% Confidence limits. 
** 95% Confidence limits. 
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sion at the doses tested are recorded as inactive 
(table 2). 
3. Results and discussion 
The data on the inhibition of the oxotremorine 
induced tremor in mice are summarized in table 2. 
Fig. 1 shows the assay results after regression analysis. 
The intercept on the abscissa describes the dosage of 
the peptide which requires a doubling of the median 
effective dosage of oxotremorine. Compound 5 has 
been utilized as a control since this compound is a 
specific antagonist to oxotremorine [ 161 and it has 
also been selected for further evaluation in clinical 
trials. 
As seen in table 2, MIF will inhibit the oxotremor- 
ine induced tremor at a dosage of 105 pmol/kg. The 
replacement of the Pro moiety in MIF withqlu 
gives a peptide=lu-Leu-Gly-NH* (2) which is 
almost twice as potent as MIF. TRH and its two 
analogs Leu’-TRH (3) and Gly2-TRH (4) are com- 
pletely inactive, while Thi2-TRH (I) is about 5 
times as potent as MIF. Comparison on a molar basis 
shows that compound 5 is only about twice as active 
as Thi2-TRH (I). The high potency of Thi2---TRH 
(I) in comparison with the inactivity of TRH is 
interesting since (I) is a very active analog of TRH in 
releasing thyrotropin (TSH) from the pituitary. Hence 
when tested in mice Thi2TRH (I) has about 30% 
of the activity of TRH and in an in vitro system, using 
isolated rat pituitaries, (I) shows as much as 77% of the 
activity of TRH [ 181. Leu’ -TRH (3) is also a rather 
potent analog of TRH having about 2% of its activity 
[ 181, while Gly’-TRH (4) has no TRH activity [ 131. 
Redding et al. [ 191 have recently demonstrated 
that the half-life of MIF in plasma in rats is approxima- 
tely 9 min and that no intact tripeptide was found in 
the urine 1 hr after the administration. The first step 
in the inactivation appears to be the cleavage of the 
Pro-Leu bond with formation of Pro and Leu-Gly- 
NH2. The higher potency of Qlu-Leu-Gly-NH2 
(2) in comparison with MIF may therefore be due to 
an increased stability against plasma inactivation. 
Since we administered MIF 1 hr before the administra- 
tion of oxotremorine it is likely that inhibition of the 
tremor is due to a secondary process induced by MIF 
and not by a competitive inhibition as is the case with 
104 
compound 5 [ 161. The inactivity of TRH in this study 
in contrast to the high activity of its potent analog 
Thi-TRH (I) could indicate that MIF and Thi’-TRH 
are acting differently. 
One of the effects of L-dopa in the treatment of 
Parkinson’s disease appears to be the replenishing of 
depleted dopamine in extrapyrimidal centers and 
thereby increasing the amount of dopamine available 
to the receptors [20]. The demonstration that MIF, 
in experimental animals, potentiates the behavioural 
effects of L-dopa and presumably accelerates the turn- 
over rates of dopamine [8] may indicate a mechanism 
of action of MIF to inhibit a Parkinson-like tremor. 
Further evaluation of MIF or other peptides, like those 
described in this communication, may suggest benefi- 
cial effects in the treatment of parkinsonian patients. 
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